Preferred Label : Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate IBI3005;
NCIt synonyms : ADC IBI3005; EGFR x HER3 Bispecific ADC IBI3005; Anti-EGFR/HER3 Bispecific ADC IBI3005; Anti-EGFR/Anti-HER3 Bispecific ADC IBI3005; Anti-EGFR/Anti-HER3 ADC IBI3005;
NCIt definition : An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against
the tumor associated antigens (TAAs) human epidermal growth factor receptor (EGFR;
HER1; ErbB1), and human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated
to a camptothecin derivative, with potential antineoplastic activity. Upon administration,
anti-EGFR/anti-HER3 bispecific ADC IBI3005 targets and simultaneously binds to EGFR
and HER3 expressed on tumor cells. This blocks EGFR activation by ligands and EGFR-mediated
signaling. Upon binding and internalization, the camptothecin derivative is released
and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and
resulting in cell cycle arrest and tumor cell apoptosis in EGFR- and HER3-expressing
tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays
a key role in tumor cell proliferation and tumor vascularization. HER3, a member of
the EGFR family of receptor tyrosine kinases, is frequently overexpressed in tumors.;
Molecule name : IBI 3005; IBI-3005;
Origin ID : C216084;
concept_is_in_subset
- has_target
